Skip to content
HowShorted

Viking Therapeutics, Inc. short interest in 2020

In 2020, Viking Therapeutics, Inc.'s disclosed short interest ran from 22.72% of shares outstanding on 15 Jan 2020 to 12.44% on 31 Dec 2020, a change of -10.28 percentage points. The year's high was 22.96% on 28 Feb 2020 and its low 11.98% on 31 Aug 2020, averaging 16.23% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.07 days on 14 Feb 2020. Full history: Viking Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Viking Therapeutics, Inc. in 2020

2020 in figures

Start of year
22.72% (15 Jan 2020)
End of year
12.44% (31 Dec 2020)
Change
-10.28 pp
High
22.96% (28 Feb 2020)
Low
11.98% (31 Aug 2020)
Average
16.23%
Highest days to cover
21.07 (14 Feb 2020)
SEC filings marked
7

Every report in 2020

Viking Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202022.72%16.78
31 Jan 202021.25%15.60
14 Feb 202020.65%21.07
28 Feb 202022.96%11.6010-K filed
13 Mar 202020.33%10.41
31 Mar 202020.34%8.40
15 Apr 202018.77%8.68
30 Apr 202017.14%10.0010-Q filed, results (8-K)
15 May 202016.88%6.69
29 May 202015.45%7.37
15 Jun 202015.13%7.78
30 Jun 202016.41%8.00
15 Jul 202013.70%8.00
31 Jul 202014.55%9.8810-Q filed, results (8-K)
14 Aug 202011.99%9.74
31 Aug 202011.98%7.35
15 Sep 202012.84%7.66
30 Sep 202015.40%9.28
15 Oct 202014.26%10.53
30 Oct 202013.89%9.5110-Q filed, results (8-K)
13 Nov 202014.68%11.71
30 Nov 202013.65%9.58
15 Dec 202012.08%7.58
31 Dec 202012.44%7.09

See also: Viking Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.